PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS

The Government of the Russian Federation approved the State strategy of combating the spread of HIV aimed at prevention of HIV epidemic. One of the goals of the Strategy is to increase the coverage of antiretroviral therapy for people infected with HIV, which includes extensive use of generic drugs. In order for a generic drug to be authorised, the applicant has to submit a report on the results of the bioequivalence studies in which the generic product was compared to the reference product. Atazanavir is an antiretroviral drug, which is also the drug of choice for the treatment and prevention of mother-to-child transmission of HIV. The aim of this study was to analyze the protocols and reports of atazanavir products bioequivalence studies, which were submitted for expert examination  to the FSBI “SCEEMP” of the Ministry of Health of the Russian Federation, and to prepare recommendations  for planning of bioequivalence studies of atazanavir products. The analysis of a number of studies revealed significant differences in the study design and number of subjects. The main reason for these differences is the conflicting data on the intrasubject coefficient of variation of atazanavir, which means that atazanavir may be considered a highly variable drug. The analysis helped to formulate  recommendations for the design of bioequivalence  studies of atazanavir products,  including studies of the maximum dose, studies under fed conditions, and consideration  of atazanavir variation when planning the study design.

1. Directive of the Government of the Russian Federation, October 20, 2016, No. 2203-r «On approval of the State strategy to combat the spread of HIV in Russia through 2020 and beyond» (In Russ.)

2. Federal Law of the Russian Federation, April 12, 2010, No. 61-FZ «On circulation of medicines» (In Russ.)

3. Guidance on evaluation of medicines. V. I. Moscow: Grif i K; 2013 (In Russ.)

4. Decision of the Council of the Eurasian economic commission, November 3, 2016, No. 85 «On approval of Rules of conducting bioequivalence studies of medicines within the framework of the Eurasian Economic Union» (In Russ.)

5. Investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1). EMA. London; 2010.

6. Reyataz® prescribing information. State register of medicines (In Russ.) Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0aba4c49-64cd-4b90-95e7-07d4f758f6d6&t=178f2068-1800-407e-85dd-c36b690e56bf

7. Pokrovsky VV, Yurin OG, Kravchenko AV, Belyaeva VV, Ermak TN, Kanestri VG, et al. National recommendation on dispensary observation and treatment of person living with HIV (clinical protocol). Epidemiologiya i infektsionnye bolezni. Aktualnye voprosy = Epidemiology and Infectious Diseases. Current Items. 2016;(6, Suppl.) (In Russ.)

8. Atazanavir. Questions of practice. Moscow: The Social Partnership Development Fund; 2011 (In Russ.)

9. Dolin R, Masur H, Saag M, eds. AIDS Therapy. 3rd ed. New York: Elsevier; 2008.

10. Full prescribing information for Reyataz (Revised: September 2016). US FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021567s040,206352s005lbl.pdf

11. Reyataz. Summary of product characteristics. EMA. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000494/WC500056380.pdf

12. Guidance on Atazanavir Sulfate. US FDA. Available from: https:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm082565.pdf

13. Shimpi S. Bioequivalence study recommendation for atazanavir sulfate capsules by US FDA and a contrary view. Open Access Scientific Reports. 2012;1(8):388. https://doi.org/10.4172/scientificreports.388

14. Bondareva IB, Gerasimov VB, Drozhzhin AP, Zherdev VP, Kolyvanov GB, Kondratenko SN, et al. Conducting qualitative studies of bioequivalence of drugs. Guidelines of the Ministry of Health and Social Development of the Russian Federation, August 10, 2004. Klinicheskaya farmakokinetika = Clinical Pharmacokinetics. 2005;(1):2–14 (In Russ.)

15. Atazanavir Mylan: EPAR — Public assessment report (EMA/503216/2016, June 23, 2016). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004048/WC500220527.pdf

16. Atazanavir (as Sulfate)/Ritonavir 300mg/100mg Tablets (Mylan Laboratories Ltd), HA507. WHO Public assessment report, Part 6, January 2013. Available from: https://extranet.who.int/prequal/sites/default/files/documents/HA507Part6v1.pdf

17. Bhushan I, Deshmukh A, Chakraborty S, Dixit A, Shetiya P, Kothawade U, et al. Open label, randomized, crossover, single-dose, bioavailability evaluation of Atazanavir/Ritonavir FDC tablets 300 mg/100 mg with that of REYATAZ 300 mg and Norvir 100 mg under fed and fasting conditions. 20th International AIDS Conference. Melbourne, Australia, July 20–25, 2014. Melbourne; 2014. Available from: http://pag.aids2014.org/EPosterHandler.axd?aid=1884

18. Sevinsky H, Tao X, Wang R, Ravindran P, Sims K, Xu X, et al. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir Ther. 2015;20(5):493–500. https:// doi.org/10.3851/IMP2913

19. Norvir® prescribing information. State register of medicines (In Russ.) Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c1fc79e1-5c2b-4777-8a91-ba473474c0b2&t=221d8480-6641-495f-9a5e-800947ecf611

20. Romodanovsky DP, Dranitsyna MA, Goryachev DV, Niyazov RR, Gavrishina EV. Design planning and evaluation of bioequivalence results of highly variable preparations based on rosuvastatin. Eksperimentalnaya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2015;78(6):19–25 (In Russ.)

21. Romodanovsky DP, Eremenkova TV, Dranitsyna MA, Goryachev DV, Niyazov RR, Gavrishina EV, Merkulov VA. Highly variable medicines — specific aspects of bioequivalence studies. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(4):5–10 (in Russ.)

22. Bioavailability and bioequivalence studies submitted in NDAs or INDs — General considerations. US FDA. 2014.

23. Haidar SH, Davit B, Chen ML, Conner D, Lee L, Li QH, et al. Bioequivalence approaches for highly variable drugs and drug products. Pharm Res. 2008;25(1):237–41. https://doi.org/10.1007/s11095-007-9434-x